Merck & Co Inc (NYSE:MRK) on Thursday said the Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65), met its primary endpoint of progression-free survival (PFS) for platinum-resistant recurrent ...
The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years.
Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely driven by ...
The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...
Hosted on MSN
Mounjaro overtakes blockbuster cancer therapy Keytruda to become world's best-selling drug
US-based pharma giant Eli Lilly's diabetes and obesity drug Mounjaro has emerged as the world's top-selling medicine, overtaking Merck's blockbuster cancer therapy Keytruda in a major shift for the ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s best-selling medication. Mounjaro generated $8.7 billion for Lilly in the first ...
Merck & Co. stock gets a Sunday background check: how the US pharma group earns much of its money with cancer blockbuster Keytruda, what its broader pipeline looks like, and where the New York-listed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results